Modality
Bispecific Ab
MOA
GLP-1ag
Target
BCMA
Pathway
Proteasome
PNHAlzheimer'sOCD
Development Pipeline
Preclinical
~Mar 2021
→ ~Jun 2022
Phase 1
~Sep 2022
→ ~Dec 2023
Phase 2
Mar 2024
→ Sep 2031
Phase 2Current
NCT05123948
533 pts·Alzheimer's
2024-06→2028-01·Active
NCT08715725
2,289 pts·OCD
2024-03→2031-09·Active
2,822 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-01-041.8y awayPh2 Data· Alzheimer's
2031-09-085.4y awayPh2 Data· OCD
Trial Timeline
Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2
Active
P2
Active
Catalysts
Ph2 Data
2028-01-04 · 1.8y away
Alzheimer's
Ph2 Data
2031-09-08 · 5.4y away
OCD
Active|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05123948 | Phase 2 | Alzheimer's | Active | 533 | EFS |
| NCT08715725 | Phase 2 | OCD | Active | 2289 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| REG-2328 | Regeneron | Phase 1 | BCMA | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA |